文献速递消化、代谢与肾脏急症

大承气汤治疗急性胰腺炎临床疗效的观察与分析

[Observation and analysis on clinical efficacy of Dachengqi decoction for acute pancreatitis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论大承气汤联合奥曲肽可提高轻症及中度重症急性胰腺炎患者的临床总有效率(93.75% vs. 71.88%),并更明显降低IL-6、PCT、CRP。

该研究纳入2018年3月至2021年2月上海市中西医结合医院收治的68例轻症急性胰腺炎(MAP)和中度重症急性胰腺炎(MSAP)患者,随机分为西医治疗组(奥曲肽+对症治疗)和大承气汤组(西医常规治疗基础上口服大承气汤100 mL,每日2次),观察7天。最终64例纳入分析,每组32例。治疗7天后两组炎症指标和血清淀粉酶均较治疗前显著下降(均P<0.05),大承气汤组IL-6、PCT、CRP下降更明显(均P<0.05);大承气汤组临床总有效率显著高于西医治疗组[93.75%(30/32)vs. 71.88%(23/32),P<0.05]。两组治疗观察期间均无明显不良事件。

要点

  • 大承气汤联合奥曲肽治疗MAP/MSAP,临床总有效率93.75%(30/32)vs. 西医治疗组71.88%(23/32),P<0.05。
  • 治疗7天,大承气汤组IL-6、PCT、CRP下降幅度均显著大于西医治疗组(均P<0.05)。
  • 两组治疗7天后WBC、IL-6、PCT、CRP、血清淀粉酶均较治疗前显著下降(均P<0.05)。
  • 大承气汤用法为西医常规治疗基础上口服100 mL,每日2次,观察7天。
  • 两组治疗观察期间均无明显不良事件。

适用人群与场景

  • 2018年3月至2021年2月上海市中西医结合医院收治的轻症急性胰腺炎(MAP)和中度重症急性胰腺炎(MSAP)患者,共68例纳入,最终64例分析。

处置流程与药物剂量

  • 西医治疗组:奥曲肽+对症治疗。
  • 大承气汤组:在西医常规治疗(奥曲肽+对症治疗)基础上口服大承气汤100 mL,每日2次;两组观察时间均为7天。

研究设计与关键结果

  • 研究类型为随机对照研究,纳入68例MAP/MSAP患者,随机分为西医治疗组和大承气汤组,最终64例纳入分析(每组32例);4例因未获取标本或放弃治疗被排除。
  • 治疗前两组炎症指标和血清淀粉酶水平差异均无统计学意义。
  • 治疗7天,西医治疗组各指标较治疗前显著下降:WBC(×10⁹/L)5.94±2.08 vs. 11.81±3.66,IL-6(ng/L)7.22(5.72,14.23)vs. 30.13(15.77,85.37),PCT(μg/L)0.068(0.052,0.128)vs. 0.290(0.231,0.428),CRP(mg/L)26.0(18.3,35.8)vs. 112.0(62.0,126.0),Amy(U/L)77(57,116)vs. 352(162,1576),均P<0.05。
  • 治疗7天,大承气汤组各指标较治疗前显著下降:WBC(×10⁹/L)5.56±2.04 vs. 12.22±2.85,IL-6(ng/L)5.70(3.26,11.06)vs. 50.30(23.99,88.32),PCT(μg/L)0.038(0.028,0.808)vs. 0.308(0.129,0.462),CRP(mg/L)11.0(3.5,24.0)vs. 150.0(75.0,193.0),Amy(U/L)78(57,104)vs. 447(336,718),均P<0.05。
  • 大承气汤组治疗后IL-6、PCT、CRP下降程度均较西医治疗组更明显(均P<0.05)。
  • 大承气汤组临床总有效率显著高于西医治疗组[93.75%(30/32)vs. 71.88%(23/32),P<0.05]。
  • 两组治疗观察期间均无明显不良事件。

证据类型、等级与局限

  • 证据类型:随机对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,大承气汤联合奥曲肽治疗可提高急性胰腺炎患者的临床疗效,其机制可能与降低炎症因子水平、抑制炎症反应及调节血清淀粉酶水平有关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the clinical efficacy of Dachengqi decoction combined with octreotide in the treatment of patients with acute pancreatitis (AP).

METHODS: From March 2018 to February 2021, a total of 68 patients with mild acute pancreatitis (MAP) and moderately severe acute pancreatitis (MSAP) admitted to Shanghai Traditional Chinese Medicine-Integrated Hospital were included, and they were randomly divided into western medicine treatment group and Dachengqi decoction group. The patients in the western medicine treatment group received conventional western medicine (octreotide+symptomatic treatment); in the Dachengqi decoction group, 100 mL of Dachengqi decoction was taken orally on the basis of conventional western medicine, twice a day; the observation time for both groups was 7 days. The levels of inflammation parameters [white blood cell count (WBC), interleukin-6 (IL-6), procalcitonin (PCT), C-reactive protein (CRP)] and serum amylase (Amy) before and after treatment of patients between the two groups, as well as the occurrence of clinical efficacy indicators and adverse reactions were compared.

RESULTS: Among the 68 included patients, 4 were excluded because the specimen was not obtained or the patient gave up the treatment. A total of 64 patients were finally enrolled in the analysis, including 32 cases in the Dachengqi decoction group and 32 cases in the western medicine treatment group respectively. There was no statistically significant difference in inflammation parameters or serum Amy levels before treatment between the two groups. At 7 days of treatment, the inflammatory parameters and serum Amy levels of the two groups were significantly lower than those before treatment [western medicine treatment group: WBC (×109/L) was 5.94±2.08 vs. 11.81±3.66, IL-6 (ng/L) was 7.22 (5.72, 14.23) vs. 30.13 (15.77, 85.37), PCT (μg/L) was 0.068 (0.052, 0.128) vs. 0.290 (0.231, 0.428), CRP (mg/L) was 26.0 (18.3, 35.8) vs. 112.0 (62.0, 126.0), Amy (U/L) was 77 (57, 116) vs. 352 (162, 1 576); Dachengqi decoction group: WBC (×109/L) was 5.56±2.04 vs. 12.22±2.85, IL-6 (ng/L) was 5.70 (3.26, 11.06) was 50.30 (23.99, 88.32), PCT (μg/L) was 0.038 (0.028, 0.808) vs. 0.308 (0.129, 0.462), CRP (mg/L) was 11.0 (3.5, 24.0) vs. 150.0 (75.0. 193.0), Amy (U/L) was 78 (57, 104) vs. 447 (336, 718); all P < 0.05], and the levels of IL-6, PCT, and CRP decreased more significantly after treatment in the Dachengqi decoction group (all P < 0.05). The total clinical effective rate of patients in the Dachengqi decoction group was significantly higher than that of the western medicine treatment group [93.75% (30/32) vs. 71.88% (23/32), P < 0.05]. There was no obvious adverse event during the treatment and observation period in the two groups.

CONCLUSIONS: Dachengqi decoction combined with octreotide therapy could improve the clinical efficacy of AP patients, and its mechanism might be related to reducing the level of inflammatory factors, thereby inhibiting the inflammatory response, and regulating the level of serum Amy.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Li J, Xiao T, Cao H, et al. [Observation and analysis on clinical efficacy of Dachengqi decoction for acute pancreatitis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35307068. doi:10.3760/cma.j.cn121430-20210714-01046

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。